These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
Pubmed for Handhelds
PUBMED FOR HANDHELDS
Journal Abstract Search
290 related items for PubMed ID: 11428736
1. Olopatadine ophthalmic solution adjunctive to loratadine compared with loratadine alone in patients with active seasonal allergic conjunctivitis symptoms. Lanier BQ, Gross RD, Marks BB, Cockrum PC, Juniper EF. Ann Allergy Asthma Immunol; 2001 Jun; 86(6):641-8. PubMed ID: 11428736 [Abstract] [Full Text] [Related]
2. The added benefit of local Patanol therapy when combined with systemic Claritin for the inhibition of ocular itching in the conjunctival antigen challenge model. Abelson MB, Lanier RQ. Acta Ophthalmol Scand Suppl; 1999 Jun; (228):53-6. PubMed ID: 10337434 [Abstract] [Full Text] [Related]
3. Efficacy and comfort of olopatadine 0.2% versus epinastine 0.05% ophthalmic solution for treating itching and redness induced by conjunctival allergen challenge. Mah FS, Rosenwasser LJ, Townsend WD, Greiner JV, Bensch G. Curr Med Res Opin; 2007 Jun; 23(6):1445-52. PubMed ID: 17559743 [Abstract] [Full Text] [Related]
4. Comparison of the effects of ketotifen fumarate 0.025% and olopatadine HCl 0.1% ophthalmic solutions in seasonal allergic conjunctivities: a 30-day, randomized, double-masked, artificial tear substitute-controlled trial. Avunduk AM, Tekelioglu Y, Turk A, Akyol N. Clin Ther; 2005 Sep; 27(9):1392-402. PubMed ID: 16291412 [Abstract] [Full Text] [Related]
5. Comparative efficacy of olopatadine 0.1% ophthalmic solution versus levocabastine 0.05% ophthalmic suspension using the conjunctival allergen challenge model. Abelson MB, Greiner JV. Curr Med Res Opin; 2004 Dec; 20(12):1953-8. PubMed ID: 15701212 [Abstract] [Full Text] [Related]
6. A comparison of the clinical efficacy of pheniramine maleate/naphazoline hydrochloride ophthalmic solution and olopatadine hydrochloride ophthalmic solution in the conjunctival allergen challenge model. Greiner JV, Udell IJ. Clin Ther; 2005 May; 27(5):568-77. PubMed ID: 15978305 [Abstract] [Full Text] [Related]
7. Efficacy of olopatadine HCI 0.1%, ketotifen fumarate 0.025%, epinastine HCI 0.05%, emedastine 0.05% and fluorometholone acetate 0.1% ophthalmic solutions for seasonal allergic conjunctivitis: a placebo-controlled environmental trial. Borazan M, Karalezli A, Akova YA, Akman A, Kiyici H, Erbek SS. Acta Ophthalmol; 2009 Aug; 87(5):549-54. PubMed ID: 18631332 [Abstract] [Full Text] [Related]
9. A randomized, double-blind, parallel-group comparison of olopatadine 0.1% ophthalmic solution versus placebo for controlling the signs and symptoms of seasonal allergic conjunctivitis and rhinoconjunctivitis. Abelson MB, Turner D. Clin Ther; 2003 Mar; 25(3):931-47. PubMed ID: 12852709 [Abstract] [Full Text] [Related]
18. Effects of a new formulation of olopatadine ophthalmic solution on nasal symptoms relative to placebo in two studies involving subjects with allergic conjunctivitis or rhinoconjunctivitis. Abelson MB, Gomes PJ, Vogelson CT, Pasquine TA, Turner FD, Wells DT, Robertson SM. Curr Med Res Opin; 2005 May; 21(5):683-91. PubMed ID: 15969867 [Abstract] [Full Text] [Related]